<resources>
    <string name="app_name">Pedia</string>
    <string name="dummy_button">Dummy Button</string>
    <string name="pedia_division">Pedia Division</string>
    <string name="brezu">Brezu</string>
    <string name="brezu_video">Brezu (Video)</string>
    <string name="clarithromycin">Clarithromycin</string>
    <string name="dibher">Dibencozide Heraclene</string>
    <string name="dibher1mg">Dibencozide Heraclene 1mg</string>
    <string name="kidzkit">Kidz Kit</string>
    <string name="montemax">Montemax</string>
    <string name="natravox">Natravox</string>
    <string name="corpvideo">Corporate Video</string>

    // BREZU

    // Slide 1

    <string name="brezu1_title">Longer Duration of Action vs. Salbunation</string>
        <string name="brezu1_text1">
            Subjects with the protection of EIA after medication using FEV1 as Parameter \n
            (n = 26)
        </string>
    <string name="brezu1_square1">Inhaled Procaterol</string>
    <string name="brezu1_square2">Oral Procaterol</string>
    <string name="brezu1_square3">Inhaled Salbutamol</string>
        <string name="brezu1_pvalue">
            <b>P value</b>\n
            5.0 hr = 0.0000001*\n
            9.5 hr = 0.00000043*\n
        </string>
        <string name="brezu1_text2">
            Both inhaled and oral procaterol provide a similar degree and duration of protection against EIA (9.5hrs)
        </string>
        <string name="brezu1_text3">
            Chu, J, Tuazon OA et al. A comparison of the protective efficacy of procaterol aerosol and
            syrup in exercise-induced asthma. Am J Resp and Critical Care Med 2000; 161 (3) A345
        </string>

    // Slide 2

    <string name="brezu2_title">Prevents Nocturnal Asthma</string>
        <string name="brezu2_text1">
            \"&#8230;that procaterol significantly inhibited the reduction in pulmonary flow rates early in the morning hours, as well as significantly decreasing the amount of wheezing measured at the time.\"
        </string>

    // Slide 3

    <string name="brezu3_title">Faster Onset of Action vs. Salbutamol</string>
    <string name="brezu3_text1">Comparative study on Bronchadilating Effects of Procaterol and Salbutamol</string>
    <string name="brezu3_choice1">Salbutamol</string>
    <string name="brezu3_choice2">Procaterol</string>
    <string name="brezu3_value">Salbutamol (n = 25)\nProcaterol (n = 25)</string>

    // Slide 4

    <string name="brezu4_title">No Drug Tolerance</string>
        <string name="brezu4_text1">
            The effectiveness of Procaterol was maintained through 3 months of treatment unlike Salbutamol, which appeared to decrease.
        </string>
    <string name="brezu4_caption1">AFTER 1 MONTH</string>
    <string name="brezu4_caption2">AFTER 3 MONTHS</string>
        <string name="brezu4_text2">
            Comparison of mean percent of FEV1 from predose values during 8hr. postdose between: \n
            Group I: received procaterol 0.05 mg twice daily for 2wk followed by 0.10mg twice daily for 10wk. \n
            Group II: received Salbutamol 2mg three times a day for 2wk followed by 4mg three times aday for 10wk.
        </string>

    // CLARITHROMYCIN

    // Slide 1

    <string name="clar_caps">CLARITHROMYCIN</string>
    <string name="clar1_title">Clarithro - Natrapharm</string>
        <string name="clar1_dosage">
            250mg / 5mL suspension\n
            125mg / 5mL suspension
        </string>

    // Slide 2

    <string name="clar2_title">Indications</string>
        <string name="clar2_text1">&#8226; LOWER RESPIRATORY TRACT INFECTION (E.G. BRONCHITIS, PNEUMONIA)
            \n&#8226; UPPER RESPIRATORY TRACT INFECTION (E.G. STREPTOCOCCAL PHARYNGITIS)
            \n&#8226; SKIN AND SKIN STRUCTURE INFECTIONS (E.G. IMPETIGO, FOLLICULITIS, CELLULITIS)
            \n&#8226; DISSEMINATED OR LOCALIZED MYCOBACTERIAL INFECTIONS DUE TO <i>MYCOBACTERIUM</i> OR <i>MYCOBACTERIUM INTRA CELLULARE</i>
            \n&#8226; LOCALIZED INFECTIONS DUE TO <i>MYCOBACTERIUM CHELONAE, MYCOBACTERIUM FORTUITUIM,</i> OR <i>MYCOBACTERIUM KANSAII</i>
        </string>

    // Slide 3

        <string name="clar3_title">
            Dosage in Patients with Renal Impairment
        </string>
        <string name="clar3_text1">
            In children with creatinine clearance with less than 30mL min., the dosage of CLARITHROMYCIN should be reduced by one-half.
            250mg once daily or 250mg twice on more severe infections. Dosage should not be continued beyond 14 days in these patients.
        </string>

    // Slide 4

        <string name="clar4_title">
            Dosage in Patients with Mycobacterial Infection
        </string>
        <string name="clar4_text1">
            In children with sisseminated or localized mycobacterial infection (M. Avium, M. Intracellulare, M. Chelonae,
            M. Fortiumtum, M. Kansasii), the recommended dose is 15 to 30 mg/kg CLARITHROMTHYCON per day divided in to 2 doses.
        </string>

    // Slide 5

        <string name="clar5_text1">
            The combination of a beta-lactam plus a macrolide could be suggested in the
            first-line treatment of CAp in the immunocompetent children aged 2 to 5 years old.
        </string>
        <string name="clar5_text2">
            Esposito et al. Characteristics of Streptococcus pneumonia and Atypical Bacterial Infection
            in Children 2 to 5 years of age with Community-Acquired Pneumonia.\n
            Clinical Diseases 2002; \n
            35:1345-52
        </string>

    // Slide 6

        <string name="clar6_text1">
            Primary combination treatment with MACROLIDES in the areas where there is a high prevalence of atypical organism.
        </string>
        <string name="clar6_text2">
            Chetty K. Thomson AH. Management of Community-Acquired Pneumonia in Children.\n
            Paediatr Drugs.\n
            2007:9(6)-401-11
        </string>

    // Slide 7

        <string name="clar7_text1">
            Children &lt; 8kg or &lt; 18lbs. should be dosed on a per kg or per lb. basis (approx. 7,5 mg/kg BID or 3.4 mg/lb BIF)
        </string>

    // Heraclene

    // Slide 1

    <string name="dibher_boxname">Dibencozide</string>
    <string name="dibher_medname">Heraclene </string>
    <string name="dibher1_title">For Picky and Fussy Eaters</string>
    <string name="dibher1_subtitle">Children with little or no appetite</string>
    <string name="dibher1_text1">The only protein building, non-sedating appetite stimulant</string>

    // Slide 2

    <string name="dibher2_title">Protein Building Process</string>
        <string name="dibher2_text1">
            Acts as the key coenzyme in the activation of incorporation of amino to form protein molecules
        </string>
        <string name="dibher2_text2">
            Contributes to accelerated formation and repair of bady tissues
        </string>
        <string name="dibher2_text3">
            Facilitates optimum utilization of dietary protein intake
        </string>

    // Slide 3

    <string name="dibher3_title">Appetite Stimulant</string>
        <string name="dibher3_text1">
            As amino acid incorporation is accelerated, more polypeptide chains are formed in to bigger protein molecules,
            thus, the artificial lack of amino acid in the amino acid pool. This results to stimulation of appetite.
        </string>
        <string name="dibher3_text2">
            \"There is a marked effect upon appetite\" after 7 to 31 days of treatment with Heraclene.
        </string>

    // Slide 4

        <string name="dibher4_check1">
            Non-Sedating\n
            Will not cause drowsiness
        </string>
        <string name="dibher4_check2">
            Excellent Tolerance\n
            No side effects\n
            No contraindications
        </string>
        <string name="dibher4_check3">
            Convenient Capsule Form\n
            Tasteless and Odorless\n
            Child will hardly notice medicine
        </string>

    // Slide 5

    <string name="dibher5_title1">Prescription Information</string>
        <string name="dibher5_text1">
            Formulation\n
            Each Capsule contains Dibencozide - 1mg
        </string>
    <string name="dibher5_title2">Actions</string>
        <string name="dibher5_text2">
            Dibencozide increases the protein \"efficiency coefficient\" (i.e. the percentage of bound nutrition
            for protein build up in the body compared to ingested nitrogen with food intake). The initial sign
            of effectiveness is manisfested by a marked increase in appetite.
        </string>
        <string name="dibher5_text3">
            Thus, DIBENCOZIDE
            1. Facilitates optimum utilization of dietary intake\n
            2. Contributes to the formation and repair of body tissue\n
            3. Stimulates appetite
        </string>

    // Slide 6

    <string name="dibher6_title1">Indications</string>
        <string name="dibher6_text1">
            &#8226; Poor appetite\n
            &#8226; Adjuvant to treatment of luberculous and other chronic ailments\n
            &#8226; Convalescense  from acute infection or surgery\n
            &#8226; Faulty nutrition in older people\n
            &#8226; Premature babies, Low birth weight. Retardted growth
        </string>
    <string name="dibher6_title2">Dosage</string>
        <string name="dibher6_text2">
            Premature babies / infants:
            1 Capsule daily (Capsule may be opened. Odorless and tasteless powder can be mixed in to milk or juice.)
            Children and Adolescents:
            2-3 Capsules daily (3 capsules daily or as prescribed by Physician)
            Adults:
            2-3 Capsules daily (3 capsules daily or as prescribed by Physician)
        </string>

    // Slide 7

    <string name="dibher7_title1">Cautions</string>
        <string name="dibher7_text1">
            Food, Drugs, Devices and Cosmetics Act prohibits dispensing without prescription.
        </string>
    <string name="dibher7_title2">Presentation</string>
    <string name="dibher7_text2">Box of 100 capsules</string>
    <string name="dibher7_title3">Reference</string>
        <string name="dibher7_text3">
            1. F. Gillot and J.L. Condudal. Clinical Trial of a Non-Steroidical an Anaboloc drugs in Pediatrics L. Quest
            Medical 25 May 1968 11-899-902 \n
            2. P. Debray, Cobamide-Coenzyme in Pediatric Practice: Medicine Infantile, 1966.
        </string>

    // HERACLENE 1mg

    // Slide 1

    <string name="dibher1mg1_caption">For the most delicate of patients&#8230;</string>
    <string name="dibher1mg_subtitle">1mg Capsule</string>
    <string name="dibher1mg1_title">Promotes Weight, Promotes Health</string>
        <string name="dibher1mg1_subtitle">
            The only protein-building appetite stimulant for low birth weight and premature babies.
        </string>

    // Slide 2

    <string name="dibher1mg2_title">The only protein-building appetite stimulant</string>
    <string name="dibher1mg2_subtitle">Proven effective, proven safe for low birth weight babies</string>
        <string name="dibher1mg2_text1">
            &#8226; Prospective, double-blind, randomized, controlled trial to evaluate efficacy add safety of
                    Dibencozide in low birth weight infants &lt; 35 weeks age of gestation\n
            &#8226; Primary objective: to determine difference in mean weight gain between infants given preterm milk formula with placebo
        </string>
    <string name="dibher1mg2_result">Result:</string>
        <string name="dibher1mg2_text2">
            &#8226; Dibencozide group had statistically significant 4g/day difference in mean weight gain compared to placebo\n
            &#8226; Dibencozide group had shorter duration of intervention compared to placebo (13.2 days + vs. 15.7 days + 9.9)\n
            &#8226; Risk Ratio and NNT for sepsis, pneumonia, necrotizing enterocolitis and death: benefit towards dibencozide
        </string>

    // Slide 3

    <string name="dibher1mg3_title">Protein Builder</string>
    <string name="dibher1mg3_subtitle">The Protein Building Process</string>
        <string name="dibher1mg3_text1">
            &#8226; acts as the key coenzyme in the activation of incorporation of amino acids to form protein molecules\n
            &#8226; contributes to accelerated formation and repair of body tissues\n
            &#8226; facilitates optimum utilization of dietary protein intake
        </string>

    // Slide 4

    <string name="dibher1mg4_title1">Formulation</string>
        <string name="dibher1mg4_text1">
            Each Capsule contains Dibencozide 1mg
        </string>
    <string name="dibher1mg4_title2">Actions</string>
        <string name="dibher1mg4_text2">
            Each DIBENCOZIDE increases the protein \"efficiency coefficient\", i.e., the percentage of
            \"bound nitrogen\" for protein build up in the body compared to \"ingested nitrogen with food intake\". The initial sign of effectiveness is manifested by marked increase in appetite.
        </string>
        <string name="dibher1mg4_text3">
            Thus, DIBENCOZIDE
            1. Facilitates optimum utilization of dietary intake\n
            2. Contributes to the formation and repair of body tissue\n
            3. Stimulates appetite
        </string>
    <string name="dibher1mg4_title4">Indications</string>
        <string name="dibher1mg4_text4">
            1. Poor appetite in children and adults\n
            2. Adjuvant to treatment of tuberculosis and other chronic ailments\n
            3. Convalescence from acute infection of surgery\n
            4.Faulty nutrition in older people
        </string>
    <string name="dibher1mg4_title5">Dosage</string>
        <string name="dibher1mg4_text5">
            Children and adolescents: 1 capsule daily or as prescribed by the physician.\n
            Adults: 3 capsules daily or as prescribed by the physician.\n
            The initial sign of its effectiveness is manifested by a marked increase in appetite.
        </string>
    <string name="dibher1mg4_title6">Caution</string>
        <string name="dibher1mg4_text6">
            Food, Drugs, Devices and Cosmetics Act prohibits dispensing without prescription.
        </string>
    <string name="dibher1mg4_title7">Presentation</string>
    <string name="dibher1mg4_text7">Box of 50 capsules</string>

    // KIDZ KIT

    // Slide 1
    <string name="kidzkit1_suspension">suspension</string>

    <string name="kidzkit_boxname1">Pyrazinamide</string>
    <string name="kidzkit_medname1">Z&#174;cure</string>
    <string name="kidzkit_dosage1">500mg/5ml</string>

    // For Slide 1 and 2

    <string name="kidzkit_boxname2">Rifampicin</string>
    <string name="kidzkit_medname2">Natricin&#174; Forte</string>
    <string name="kidzkit_dosage2">200mg/5ml</string>

    <string name="kidzkit_boxname3">Isoniazid+ Pyridoxine HCI</string>
    <string name="kidzkit_medname3">Curazid&#174; Forte</string>
    <string name="kidzkit_dosage3">200mg/10ml per 5ml syrup</string>

    // MONTEMAX

    // Slide 1

        <string name="montemax_dosage">
            4mg, 5mg, and 10mg chewable tablet
        </string>
        <string name="montemax1_subtitle1">
            Achieve control (in Asthma and Allergic Rhinitis)
        </string>
        <string name="montemax1_reminder1">
            Should be taken once daily.
        </string>
        <string name="montemax1_bullet1">
            For Asthma, the dose should be taken in the evening to prevent nocturnal attack.
        </string>
        <string name="montemax1_bullet2">
            For Allergic Rhinitis, the time of administration may be individualized to suit patient needs.
        </string>
        <string name="montemax1_bullet3">
            Patients with both Asthma and Allergic Rhinitis, should only take one tablet daily in the evening.
        </string>
        <string name="montemax1_bullet4">
            Patients below 15 years old with Asthma and or Allergic Rhinitis: one 5 mg chewable tablet daily,
            no adjustment within the age group is necessary.
        </string>
        <string name="montemax1_bullet5">
            Children between 2 to 5 years old with Asthma and/or Allergic Rhinitis: one 4mg chewable tablet daily.
        </string>

    // Slide 2

        <string name="montemax2_title">
            Recommended Asthma Medications
        </string>
    <string name="montemax2_severityHeader">Severity</string>
    <string name="montemax2_dcmHeader">Daily Controller Medication</string>
    <string name="montemax2_otherHeader">Other Options</string>

    <string name="montemax2_severity1">Mild Persistent</string>
    <string name="montemax2_severity2">Moderate Persistent</string>
    <string name="montemax2_severity3">Severe Persistent</string>

        <string name="montemax2_dcm1">
            &#8226; Inhaled glucocorticosteroid (100 - 400 &#956;g budesonide or equivalent)
        </string>
        <string name="montemax2_dcm2">
            &#8226; Inhaled glucocorticosteroid (400 - 800 &#956;g budesonide or equivalent)
        </string>
        <string name="montemax2_dcm3">
            &#8226; Inhaled glucocorticosteroid (&gt; 800 &#956;g budesonide or equivalent)
            plus one or more of the following, if needed:\n
            a. Sustained-release theophylline\n
            b. Cromone\n
            c. Leukotriene modifier - MONTELUKAST
        </string>

        <string name="montemax2_other1or3">
            &#8226; Sustained-release theophylline\n
            &#8226; Cromone\n
            &#8226; Leukotriene modifier - MONTELUKAST
        </string>

        <string name="montemax2_other2">
            &#8226; Inhaled glucocorticosteroid (&lt; 800g budesonide or equivalent) along with any of the following:\n
            a. sustained-release theophylline\n
            b. plus long-acting inhaled &#946;2- agonist\n
            c. Leukotriene modifier - MONTELUKAST
        </string>

    // Slide 3

        <string name="montemax3_title">
            Classification of Allergic Rhinitis: ARIA Guidelines
        </string>
    <string name="montemax3_subtitle1">Intermittent</string>
    <string name="montemax3_subtitle2">Persistent</string>
    <string name="montemax3_subtitle3">Mild</string>
    <string name="montemax3_subtitle4">Moderate - Severe</string>

        <string name="montemax3_interper">
            &gt; 4 days a week or &lt; 4 weeks
        </string>
        <string name="montemax3_mild">
            &#8226; normal sleep\n
            &#8226; no impairment of daily activities, sport, or leisure\n
            &#8226; normal work and school\n
            &#8226; no troublesome symptoms\n
        </string>
        <string name="montemax3_moderate">
            &#8226; abnormal sleep\n
            &#8226; impairment of daily activities, sport, or leisure\n
            &#8226; abnormal work and school\n
            &#8226; troublesome symptoms\n
        </string>

    // Slide 4

        <string name="montemax4_title">
            Management of Allergic Rhinitis: ARIA Guidelines
        </string>

    // NATRAVOX

    // Slide 1

    <string name="natravox_boxname">Co-amoxiclave</string>
        <string name="natravox_dosage">
            156mg/5mL | 228/5mL \n
            312mg/5mL | 457mg/5mL/suspension
        </string>
        <string name="natravox1_text">
            \"The prudent step-up against key pathogens.\"
        </string>

    // Slide 2

        <string name="natravox2_title">
            For Optimal Antimicrobial Treatment in Respiratory Tract Infections
        </string>
    <string name="natravox2_choice1">Aim for Bacteria Eradication</string>
    <string name="natravox2_choice2">Minimize Resistance Emergence</string>
    <string name="natravox2_choice3">Choose&#8230;</string>

    // Slide 3

        <string name="natravox3_title">
            In the treatment of Respiratory Tract Infections
        </string>
        <string name="natravox3_text1">
            CLINICAL CURE + BACTERIAL ERADICATION
        </string>
    <string name="natravox3_equals">=</string>
        <string name="natravox3_text2">
            Prevention of RELAPSE and ANTIBIOTIC RESISTANCE
        </string>

    // Slide 4

        <string name="natravox4_text1">
            \"When evaluating the efficacy of antibiotics for treatment of RTI,
            assessment of clinical cure may not be the most relevant parameter,
            as if it may not related to microbiological medication&#8230; of infecting pathogens.\"
        </string>

    // Slide 5

        <string name="natravox5_text1">
            \"&#8230;failure to eradicate bacteria may promote the emergence and dissemination of antimicrobial-resistant clones.
            Pharmakinetic or Pharmadynamic parameters can be used to predict the bacteriological efficay of antimicrobial therapy.
            In conclusion, the aim of antimicrobial therapy in respiratory infection should be the eradication of the infecting organisms.\"
        </string>

    // Slide 6

        <string name="natravox6_title">
            The Three Most Common Pathogens of the Respiratory Tract Infections are:
        </string>
    <string name="natravox6_text1">Streotoccocus Pneumoniae Gram (+)</string>
    <string name="natravox6_text2">Haemophilus Influenzae Gram (+)</string>
    <string name="natravox6_text3">Moraxella Catarrhalis Gram (+)</string>

    // Slide 7
        <string name="natravox7_text1">
            \"&#8230;Streotoccocus Pneumoniae, Haemophilus influenzae and Moraxella Catarrhalis are the most common community-acquired
            respiratory bacterial pathogens, and an increase in their resistance to the orally administered antimicrobial agents used
            to treat these infections has emerged as a world-wide problem.\"
        </string>

    // Slide 8
    <string name="natravox8_title">Indications</string>
    <string name="natravox8_subtitle1">Genito Urinary Tract and Abdominal Infections</string>
        <string name="natravox8_text1">
            Examples include cystitis (especially when recurrent or not complicated, but not prostatitis) septic abortion,
            pelvic or puerperal sepsis and intra-abdominal sepsis. These infections are often caused by Enterobacteriaceae
            (mainly Escherichia coli), Staphyloccocus saprophyticus, and Enteroccocus species.
        </string>
    <string name="natravox8_subtitle2">Skin and Soft Tissues Infections</string>
        <string name="natravox8_text2">
            Examples include cellulitis, animal bites, and severe dental abcess with spreading cellulitis caused by Staphyloccocus
            aureus, Streptoccocus pyogenes, and Bacteriodes species.
        </string>

    // Slide 9
        <string name="natravox9_text1">
            Convenient step-up against key Pathogens.
        </string>
        <string name="natravox9_text2">
            Well tolerated and safe for children.
        </string>
        <string name="natravox9_text3">
            No DIDP (Diisodecyl Phthalate) content.
        </string>

    <!-- Other stuff -->
    <string name="hello_blank_fragment">Hello blank fragment</string>
    <string name="title_activity_slider">Slider</string>
    <string name="profile_user_name">User Name</string>
    <string name="profile_department_name">Department Name</string>

    <string name="menu_prompt">Choose a page</string>

</resources>
